XTEND-Kids is the first assessment of once-weekly ALTUVOCT® prophylaxis in previously treated children Results indicate highly effective bleed protection in children under 12 years of age with severe haemophilia A Published in NEJM, the pivotal XTEND-Kids study shows ALTUVOCT met primary and key secondary endpoints, which included occurrence of factor VIII inhibitors and annualised bleed rates (ABRs). Results revealed no development of factor VIII inhibitors and sustained protection from bleeding events wit ...

Thomas Grenier As one of the largest providers of influenza vaccines to the United States with a range of options, Sanofi meets immunization needs across the lifespan, from children as young as six months of age through adults 65 years of age and older. This year's 2024/25 U.S. influenza season portfolio includes Fluzone High-Dose (Influenza Vaccine), Flublok (Influenza Vaccine) and Fluzone (Influenza Vaccine). IMPORTANT SAFETY INFORMATION FOR FLUZONE® (INFLUENZA VACCINE), FLUBLOK® (INFLUENZA VACCINE), AND ...

Key Takeaways Shares of Kymera Therapeutics (KYMR) jumped Tuesday, a day after it said partner Sanofi (SNY) agreed to extend a Phase 2 trial of its experimental drug to treat certain autoimmune skin diseases. KT-474 is being studied as a treatment for patients suffering from hidradenitis suppurativa and atopic dermatitis. It targets a key protein that plays a critical role in triggering the immune system response against invading pathogens. The two companies announced their partnership in 2020, with Kymera ...

Alones Creative Approval has come late in Q2'24 I do note that current revenue estimates for VRNA for 2024 average just $7M, albeit from just six analysts. That doesn't sound like a particularly high bar to clear in the first six months of the launch. Of course those estimates could be revised upwards, and pale in comparison to a 2029 sales estimate of $1.05B GlobalData. Nonetheless is doesn't seem like a rapid launch is predicted, especially when we consider Ohtuvayre is priced at $35.4K annually. The comp ...

WATERTOWN, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, is pleased to announce that Sanofi (Nasdaq: SNY) has made a $40 million strategic investment in the Company at an as-converted price of $7.44 per share of common stock. Sanofi will purchase 537,634 of the Company's Series A non-voting preferred shares, each share of which shall be co ...

Investment Overview - Sanofi has made a strategic investment of $40 million in Vigil Neuroscience at an as-converted price of $7.44 per share of common stock, purchasing 537,634 Series A non-voting preferred shares convertible into common stock [6][7] - The investment is aimed at funding Vigil's research and development activities, particularly in the area of neurodegenerative diseases [6][2] Company Focus - Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases by restoring microglial function [3] - The company is developing precision-based therapies, including iluzanebart, a monoclonal antibody targeting TREM2 for a rare neurodegenerative disease, and VG-3927, a small molecule TREM2 agonist aimed at treating Alzheimer's disease [3][6] Strategic Implications - Sanofi's investment is seen as a validation of Vigil's precision medicine approach and strengthens Sanofi's commitment to immunoscience and neuroimmunology [2][6] - The proceeds from the investment are expected to extend Vigil's cash runway into 2026, allowing for continued development of its clinical programs [2][6]

Availability of the Q2 2024 Aide-mémoire About Sanofi Investor Relations Thomas Kudsk Larsen |+ 44 7545 513 693 | thomas.larsen@sanofi.com Alizé Kaisserian|+ 33 6 47 04 12 11 | alize.kaisserian@sanofi.com Arnaud Delépine |+ 33 6 73 69 36 93 | arnaud.delepine@sanofi.com Felix Lauscher |+ 1 908612 7239 | felix.lauscher@sanofi.com Keita Browne |+ 1 781 249 1766 | keita.browne@sanofi.com Nathalie Pham|+ 33 7 85 93 30 17 | nathalie.pham@sanofi.com Tarik Elgoutni | + 1 617 710 3587 | tarik.elgoutni@sanofi.com Thi ...

Seven oral presentations across the hemophilia portfolio reinforce Sanofi's commitment to bring potential first- and best-in-class treatments to the rare blood disorders community Interim results from the long-term XTEND-ed phase 3 study demonstrate once-weekly ALTUVIIIO continues to provide highly effective bleed protection New ATLAS phase 3 study data reinforce the potential of fitusiran to provide prophylaxis for people with hemophilia A or B, with or without inhibitors New Drug Application for fitusiran ...

STOCKHOLM, June 19, 2024 /PRNewswire/ -- Sobi® today announced the European Commission has granted Marketing Authorisation for ALTUVOCT™ (efanesoctocog alfa), for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. ALTUVOCT is a high-sustained factor VIII replacement therapy for all ages and any disease severity. Children, adolescents, and adults can experience non-haemophilia factor VIII activity levels (above 40%) for a significant part of the week with once-weekly proph ...

"We look forward to combining the powerful capabilities of Belharra's next-generation chemotherapeutics platform with Sanofi's vast expertise in immunology research and development as we work together toward discovering new therapeutics for challenging-to-treat diseases," said Jeff Jonker, CEO of Belharra. "With the ability to illuminate any pocket, on any protein, in any cell type, our platform enables perhaps the broadest and most unbiased chemoproteomic screening capabilities in the industry. Leveraging ...